Recombinant PLD1 is commonly produced in CHO cells due to their compatibility with post-translational modifications. Key steps include:
Vector Construction: Cloning of the PLD1 fragment into plasmids (e.g., PB513b-1 Vector) .
Transfection: Stable or transient expression in CHO-K1 or derived lines (e.g., CHO-hEPO) .
Validation: Confirmation via fluorescence microscopy (e.g., GFP-tagged PLD1) and qPCR .
| Parameter | Value/Observation | Source |
|---|---|---|
| Transfection Efficiency | ~80% (GFP fluorescence) | |
| PLD Activity Increase | 30–400-fold (vs. controls) | |
| Localization | Endosomes, autophagosomes |
PLD1 relocalizes to autophagosome membranes during nutrient deprivation, facilitating LC3-positive compartment expansion .
PKC Activation: PLD1-derived PA stimulates conventional PKC isoforms (α, β1/β2), enhancing downstream signaling .
mTOR Regulation: PA recruits Rheb GTPase to activate mTOR, promoting cell growth .
Cytoskeletal Remodeling: Phosphorylated cofilin binds PLD1, linking lipid signaling to actin dynamics .
Angiogenesis: PLD1 knockdown inhibits VEGF-induced endothelial cell migration and tube formation by 60–70% .
Cancer Survival: Overexpression suppresses p53-mediated apoptosis in DNA-damaged cells .
Protein Production Optimization: PLD1 modulates secretory pathway efficiency in CHO cells, impacting recombinant protein yields .
Lipid Droplet Studies: RalA-PLD1 axis drives lipid droplet growth during nutrient stress, relevant for metabolic disease research .
| Inhibitor/Modulator | Target | Effect on PLD1 |
|---|---|---|
| VU0359595 | PLD1-specific | Blocks PA production in CHO-M1 |
| 1-Butanol | Substrate shunt | Reduces PA-dependent signaling |
| siRNA-PLD1 | Gene silencing | Decreases LC3-II/LC3-I ratio |
| Feature | PLD1 | PLD2 |
|---|---|---|
| Localization | Endosomes, autophagosomes | Plasma membrane |
| Activation Mechanism | PKC, Arf, RhoA | Minimal PKC coupling |
| Functional Role | Autophagy, survival signaling | Exocytosis, membrane repair |
KEGG: cge:100689404